Who
Matt Davidson
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Adial Pharmaceuticals; 10% owner, Verrica Pharmaceuticals.
In numbers
- Trades disclosed
- 197
- Buys
- 0
- Sells
- 160
- Bought
- $0
- Sold
- $6.0M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 19 Feb 2018
- Last trade
- 12 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —232,417 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —232,417 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —232,417 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —232,417 at $0.00 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —61,647 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,427 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,822.13 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —101.298 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —61,647 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,427 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,822.13 | filing |
| 11 Jun 2026filed 16 Jun 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —101.3 | filing |
| 9 Sep 2019filed 9 Sep 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $68K6,300 at $10.82 | filing |
| 6 Sep 2019filed 9 Sep 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $39K3,802 at $10.38 | filing |
| 6 Sep 2019filed 9 Sep 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $54K4,712 at $11.44 | filing |
| 6 Sep 2019filed 9 Sep 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $17K1,400 at $12.07 | filing |
| 5 Sep 2019filed 9 Sep 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $32K3,100 at $10.29 | filing |
| 29 Aug 2019filed 29 Aug 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $22K2,188 at $10.14 | filing |
| 27 Aug 2019filed 29 Aug 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,115500 at $10.23 | filing |
| 9 Aug 2019filed 9 Aug 2019 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K2,773 at $10.21 | filing |
News
No headline names them, or the companies they trade most, lately.